Luteinizing hormone-releasing hormone (LHRH) in rat prostate: Characterization of LHRH peptide, messenger ribonucleic acid expression, and molecular processing of LHRH in intact and castrated male rats

Nasrin Azad, Shahab Uddin, Nancy La Paglia, Lidia Kirsteins, Nicholas V. Emanuele, Ann M. Lawrence, Mark Kelley

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Continuous administration of LHRH agonist suppresses the pituitary-gonadal axis, achieving chemical castration. Thus, LHRH agonist has been used as an alternative (to surgical castration) for the treatment of steroid-dependent prostate cancer. However, recent reports have demonstrated that LHRH agonist had a direct inhibiting effect on prostate cancer cell proliferation and that cancerous prostate tissue contained a LHRH-like peptide. In this paper we are reporting for the first time that the normal rat ventral prostate contained immunoactive and bioactive LHRH as well as its precursor molecule, pro-LHRH. Our investigation showed that the LHRH concentration in prostate increased 2 weeks after castration from 1.68 ± 0.09 to 3 ± 0.2 pg/mg tissue (P < 0.001). At the same time, the concentration of pro-LHRH decreased from 149 ± 6.5 to 68 ± 6.8 pg/mg tissue (P < 0.001). Furthermore, intact rat prostate expressed LHRH mRNA, which increased 13-fold 2 weeks after castration. In summary, the prostate of intact Sprague-Dawley rats has the capacity to produce the LHRH precursor and process it to the mature decapeptide, and this production/processing increases significantly after castration.

Original languageEnglish (US)
Pages (from-to)1252-1257
Number of pages6
JournalEndocrinology
Volume133
Issue number3
DOIs
StatePublished - Sep 1993

Fingerprint

Gonadotropin-Releasing Hormone
Prostate
RNA
Peptides
Castration
Prostatic Neoplasms
Sprague Dawley Rats
Steroids
Cell Proliferation
Messenger RNA

ASJC Scopus subject areas

  • Endocrinology

Cite this

Luteinizing hormone-releasing hormone (LHRH) in rat prostate : Characterization of LHRH peptide, messenger ribonucleic acid expression, and molecular processing of LHRH in intact and castrated male rats. / Azad, Nasrin; Uddin, Shahab; Paglia, Nancy La; Kirsteins, Lidia; Emanuele, Nicholas V.; Lawrence, Ann M.; Kelley, Mark R.

In: Endocrinology, Vol. 133, No. 3, 09.1993, p. 1252-1257.

Research output: Contribution to journalArticle

Azad, Nasrin ; Uddin, Shahab ; Paglia, Nancy La ; Kirsteins, Lidia ; Emanuele, Nicholas V. ; Lawrence, Ann M. ; Kelley, Mark R. / Luteinizing hormone-releasing hormone (LHRH) in rat prostate : Characterization of LHRH peptide, messenger ribonucleic acid expression, and molecular processing of LHRH in intact and castrated male rats. In: Endocrinology. 1993 ; Vol. 133, No. 3. pp. 1252-1257.
@article{89058420a5914ab7b9e5d30b04fab9ab,
title = "Luteinizing hormone-releasing hormone (LHRH) in rat prostate: Characterization of LHRH peptide, messenger ribonucleic acid expression, and molecular processing of LHRH in intact and castrated male rats",
abstract = "Continuous administration of LHRH agonist suppresses the pituitary-gonadal axis, achieving chemical castration. Thus, LHRH agonist has been used as an alternative (to surgical castration) for the treatment of steroid-dependent prostate cancer. However, recent reports have demonstrated that LHRH agonist had a direct inhibiting effect on prostate cancer cell proliferation and that cancerous prostate tissue contained a LHRH-like peptide. In this paper we are reporting for the first time that the normal rat ventral prostate contained immunoactive and bioactive LHRH as well as its precursor molecule, pro-LHRH. Our investigation showed that the LHRH concentration in prostate increased 2 weeks after castration from 1.68 ± 0.09 to 3 ± 0.2 pg/mg tissue (P < 0.001). At the same time, the concentration of pro-LHRH decreased from 149 ± 6.5 to 68 ± 6.8 pg/mg tissue (P < 0.001). Furthermore, intact rat prostate expressed LHRH mRNA, which increased 13-fold 2 weeks after castration. In summary, the prostate of intact Sprague-Dawley rats has the capacity to produce the LHRH precursor and process it to the mature decapeptide, and this production/processing increases significantly after castration.",
author = "Nasrin Azad and Shahab Uddin and Paglia, {Nancy La} and Lidia Kirsteins and Emanuele, {Nicholas V.} and Lawrence, {Ann M.} and Kelley, {Mark R.}",
year = "1993",
month = "9",
doi = "10.1210/endo.133.3.8365367",
language = "English (US)",
volume = "133",
pages = "1252--1257",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Luteinizing hormone-releasing hormone (LHRH) in rat prostate

T2 - Characterization of LHRH peptide, messenger ribonucleic acid expression, and molecular processing of LHRH in intact and castrated male rats

AU - Azad, Nasrin

AU - Uddin, Shahab

AU - Paglia, Nancy La

AU - Kirsteins, Lidia

AU - Emanuele, Nicholas V.

AU - Lawrence, Ann M.

AU - Kelley, Mark R.

PY - 1993/9

Y1 - 1993/9

N2 - Continuous administration of LHRH agonist suppresses the pituitary-gonadal axis, achieving chemical castration. Thus, LHRH agonist has been used as an alternative (to surgical castration) for the treatment of steroid-dependent prostate cancer. However, recent reports have demonstrated that LHRH agonist had a direct inhibiting effect on prostate cancer cell proliferation and that cancerous prostate tissue contained a LHRH-like peptide. In this paper we are reporting for the first time that the normal rat ventral prostate contained immunoactive and bioactive LHRH as well as its precursor molecule, pro-LHRH. Our investigation showed that the LHRH concentration in prostate increased 2 weeks after castration from 1.68 ± 0.09 to 3 ± 0.2 pg/mg tissue (P < 0.001). At the same time, the concentration of pro-LHRH decreased from 149 ± 6.5 to 68 ± 6.8 pg/mg tissue (P < 0.001). Furthermore, intact rat prostate expressed LHRH mRNA, which increased 13-fold 2 weeks after castration. In summary, the prostate of intact Sprague-Dawley rats has the capacity to produce the LHRH precursor and process it to the mature decapeptide, and this production/processing increases significantly after castration.

AB - Continuous administration of LHRH agonist suppresses the pituitary-gonadal axis, achieving chemical castration. Thus, LHRH agonist has been used as an alternative (to surgical castration) for the treatment of steroid-dependent prostate cancer. However, recent reports have demonstrated that LHRH agonist had a direct inhibiting effect on prostate cancer cell proliferation and that cancerous prostate tissue contained a LHRH-like peptide. In this paper we are reporting for the first time that the normal rat ventral prostate contained immunoactive and bioactive LHRH as well as its precursor molecule, pro-LHRH. Our investigation showed that the LHRH concentration in prostate increased 2 weeks after castration from 1.68 ± 0.09 to 3 ± 0.2 pg/mg tissue (P < 0.001). At the same time, the concentration of pro-LHRH decreased from 149 ± 6.5 to 68 ± 6.8 pg/mg tissue (P < 0.001). Furthermore, intact rat prostate expressed LHRH mRNA, which increased 13-fold 2 weeks after castration. In summary, the prostate of intact Sprague-Dawley rats has the capacity to produce the LHRH precursor and process it to the mature decapeptide, and this production/processing increases significantly after castration.

UR - http://www.scopus.com/inward/record.url?scp=0027303703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027303703&partnerID=8YFLogxK

U2 - 10.1210/endo.133.3.8365367

DO - 10.1210/endo.133.3.8365367

M3 - Article

C2 - 8365367

AN - SCOPUS:0027303703

VL - 133

SP - 1252

EP - 1257

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 3

ER -